Drug Trial Radar · NCT03842982
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
362
Planned (sponsor's estimate)
Start
May 3, 2019
Primary completion
Feb 1, 2031
Study completion Feb 1, 2031
Sponsor
- Lead sponsor
- Centre Oscar LambretAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.
Conditions
- Ovary Neoplasms
- Ovarian Cancer
- Ovarian Carcinoma
Interventions
HIPECDrug
HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate. Administration of the dose should be according the following schedule: * 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion. * The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free Survival (DFS)Time frame: From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Brussels, Belgium
Cliniques universitaires St-Luc, Institut Roi Albert II
Brussels, Belgium
Institut de Cancérologie de l'Ouest
Angers, France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Oscar Lambret
Lille, France
Hôpital Jeanne de Flandre
Lille, France
Institut Paoli Calmettes
Marseille, France
ICM-Val d'Aurelle
Montpellier, France
Hôpital Européen Georges Pompidou
Paris, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Clinique Mathilde
Rouen, France
Centre Henri Becquerel
Rouen, France
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
Hôpital de Hautepierre
Strasbourg, France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.